Price
CHART BY
Frequently asked questions
What is Ocular's market capitalization?
The market capitalization of Ocular is $2.19B. Market capitalization is a measure of the total market value of a publicly traded company. It is calculated by multiplying the current stock price by the total number of outstanding shares.
What is the Earnings Per Share (EPS) for Ocular?
Ocular's Earnings Per Share (EPS) over the trailing twelve months (TTM) is -$1.413. EPS indicates the company's profitability on a per-share basis.
What are the analyst ratings and target price for Ocular's stock?
Currently, 12 analysts cover Ocular's stock, with a consensus target price of $27.17. Analyst ratings provide insights into the stock's expected performance.
What is Ocular's revenue over the trailing twelve months?
Over the trailing twelve months, Ocular reported a revenue of $52.05M.
What is the EBITDA for Ocular?
Ocular's Earnings before interest, taxes, depreciation, and amortization (EBITDA) over the trailing twelve months is -$308.45M. EBITDA measures the company's overall financial performance.
What is the free cash flow of Ocular?
Ocular has a free cash flow of -$255.10M. Free cash flow indicates the cash generated after accounting for cash outflows to support operations and capital assets.
How many employees does Ocular have, and what sector and industry does it belong to?
Ocular employs approximately 325 people. It operates in the Health Care sector, specifically within the Major Pharmaceuticals industry.
What is the free float of Ocular's shares?
The free float of Ocular is 200.73M. Free float refers to the number of shares available for public trading, excluding restricted shares.
Financials
- Market Cap
- $2.19B
- EPS (TTM)
- -$1.413
- Free Float
- 200.73M
- Revenue (TTM)
- $52.05M
- EBITDA (TTM)
- -$308.45M
- Free Cashflow (TTM)
- -$255.10M
Pricing
- 1D span
- $9.831$10.19
- 52W span
- $6.24$16.42
Analyst Ratings
The price target is $27.17 and the stock is covered by 12 analysts.
Buy
12
Hold
0
Sell
0
Information
Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.
- Employees
- 325
- Industries
- Major Pharmaceuticals
- Sector
- Health Care
Identifier
- Primary Ticker
- OCUL
Knockouts
Real-time data from LSX · Fundamentals & EOD data from FactSet